Data At ASH 2016 Show Strong, Lasting Efficacy Of Imbruvica® (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukaemia (CLL)
- EMEA Innovative Medicine
- Data At ASH 2016 Show Strong, Lasting Efficacy Of Imbruvica® (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukaemia (CLL)
Data At ASH 2016 Show Strong, Lasting Efficacy Of Imbruvica® (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukaemia (CLL)
- X (Twitter)
Copy link